Antagonist muscle action
Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline
Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement
X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion
X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring
England’s NICE Approves Theramex’s Uterine Fibroids Treatment
NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health
X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder
X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.